Month: June 2018
As Companies Tackle “Age-Related Diseases”, How Much Do We Know About Geriatricians?
It is encouraging to hear the news of further investment – $1B to be exact – into extending research collaboration between AbbVie and Calico focused on developing innovative therapies for “age-related diseases”. This partnership is evidence of the growing industry movement to embrace the differences across the lifespan and focus on therapies which can be tailored to this
Details
5 Reasons Why You Don’t Use Prescription Data To Identify Your KOLs
Over the years we have heard a number of concerns regarding KOLs from company employees: “I am worried that if he is asked how to use it, what will he say”? “She is not loyal to us”. “I don’t know why he is up there [speaking], he never prescribes our product”. These are the concerns
Details
Stakeholder Deep Dive: Is There More Than A Doctor In The House?
A recent Snowfish post discussed the virtues of stakeholder engagement and the advantages afforded to companies who invest in mapping their own stakeholder landscapes. While we touched upon the endless number of stakeholder categories, the nuances within them was way more than a single article could handle. We will be publishing a series of posts which will
Details
Staking Out Success In New Product Planning
New therapies entering the market face a fiercely competitive landscape and companies continue to work committedly to establish and maintain their edge. One way has been to get the right individuals and groups on board for expert guidance and to build momentum. Stakeholder engagement has always played a role in the product planning phase but
Details